Structure based drug design for HIV protease: From molecular modeling to cheminformatics

Current Topics in Medicinal Chemistry

Volumn 7, Issue 10, 2007, Pages 1030-1038

  Volarath, Patra ^a   Harrison, Robert W ^a   Weber, Irene T ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Darunavir; Docking; Drug resistant HIV; Molecular mechanics; Self organizing map; SMILES notation

Indexed keywords

AMPRENAVIR; DARUNAVIR; DNA; DOCKING PROTEIN; GENOMIC DNA; INDINAVIR; LIGAND; MOZENAVIR; NELFINAVIR; PROTEIN KINASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR; SIALIDASE INHIBITOR; TIPRANAVIR;

ACCURACY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALGORITHM; ANTIVIRAL ACTIVITY; BINDING AFFINITY; CHEMICAL STRUCTURE; COMPUTER PROGRAM; DATA MINING; DRUG DESIGN; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; FUZZY LOGIC; HUMAN; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; MOLECULAR MODEL; NONHUMAN; PHYSICAL CHEMISTRY; PREDICTION; PROTEIN STRUCTURE; PROTEIN TARGETING; QUANTUM MECHANICS; REVIEW; SIMULATION; SOLVATION; STRUCTURE ACTIVITY RELATION; VIRTUAL REALITY; VIRUS RESISTANCE;

DATABASES, FACTUAL; DRUG DESIGN; HIV PROTEASE; HIV PROTEASE INHIBITORS; MODELS, CHEMICAL; MODELS, MOLECULAR; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34447270269     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780906744     Document Type: Review

References (100)

1. Noble, M. E.; Endicott; J. A.; Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure, Science 2004, 303, 1800-1805.
2. Alymova, I. V.; Taylor, G.; Portner, A. Neuraminidase inhibitors as antiviral agents. Curr. Drug Targets Infect. Disord. 2005, 5, 401-409.
3. Wlodawer, A.; Vondrasek, J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 1998, 27, 249-284.
4. Prejdova, J.; Soucek, M.; Konvalinka, J. Determining and overcoming resistance to HIV protease inhibitors. Curr. Drug Targets Infect. Disord. 2004, 4, 137-152.
5. Shafer, R. W. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 2002, 15, 247-277.
6. Volarath, P.; Harrison, R. W. Potential-Based Simulation and Molecular Modeling. In Handbook of Theoretical and Computational Nanotechnology; Rieth, M.; Schommers, W.; Eds.; American Scientific Publishers: Forschungszentrum Karlsruhe, Germany, 2006; pp 547-587.
7. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov. 2004, 3, 935-949.
8. Perola, E.; Walters, W. P.; Charifson, P. S. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins 2004, 56, 235-249.
9. Debnath, A. K. Application of 3D-QSAR techniques in anti-HIV-1 drug design-an overview. Curr. Pharm. Des. 2005, 11, 3091-3110.
10. Kurup, A.; Mekapati, S. B.; Garg, R.; Hansch, C. HIV-1 protease inhibitors: a comparative QSAR analysis. Curr. Med. Chem. 2003, 10, 1679-1688.
11. Jonsdottir, S. O.; Jorgensen, F. S.; Brunak, S. Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates. Bioinformatics 2005, 21, 2145-2160.
12. Rodriguez-Barrios, F.; Gago, F. HIV protease inhibition: limited recent progress and advances in understanding current pitfalls. Curr. Top. Med. Chem. 2004, 4, 991-1007.
13. Rhee, S. Y.; Gonzales, M. J.; Kantor, R.; Betts, B. J.; Ravela, J.; Shafer, R. W. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003, 31, 298-303.
14. Koh, Y.; Nakata, H.; Maeda, K.; Ogata, H.; Bilcer, G.; Devasamundam, T.; Kincaid, J. F.; Boross, P.; Wang, Y.-F.; Tie, Y.; Volarath, P.; Gaddis, L.; Harrison, R. W.; Weber, I. T.; Ghosh, A. K.; Mitsuya, H. Novel bistetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) potent against multi-PI-resistant HIV in vitro. Antimicrob. Agents Chemother. 2003, 47, 3123-3129.
15. Tie, Y.; Boross, P. I.; Wang, Y.-F.; Gaddis, L.; Hussain, A. K.; Leshchenko, S.; Ghosh, A. K.; Louis, J. M.; Harrison, R. W.; Weber, I. T. High Resolution Crystal Structures of HIV-1 Protease with a Potent Non-peptide Inhibitor (UIC-94017) Active against Multi-Drug Resistant Clinical Strains. J. Mol. Biol. 2004, 338, 341-352.
16. Comba, P.; Hambley, T. W. Molecular Modeling of Inorganic Compounds. In; Eds.; Wiley, John & Sons: New York, 1995.
17. Leach, A. R. Molecular Modelling: Principles and Applications. In; Eds.; Prentice Hall: England, 2001.
18. MacKerell, A. D., Jr. Empirical Force Fields for Biological Macromolecules: Overview and Issues. J. Comp. Chem. 2004, 25, 1584-1604.
19. Weiner, S. J.; Kollman, P. A.; Nguyen, D. T.; Case, D. A. An all atom force field for simulations of proteins and nucleic acids. J. Comp. Chem. 1986, 7, 230-252.
20. Rappe, A. K.; Casewit, C. J.; Colwell, K. S.; Goddard, W. A. I.; Skiff, W. M. UFF a full periodic table force field for molecular mechanics and molecular dynamics simulations. J. Am. Chem. Soc. 1992, 114, 10024-10035.
21. Allinger, N. L.; Yuh, Y. H.; Lii, J. H. Molecular mechanics: The MM3 force field for hydrocarbons. J. Am. Chem. Soc. 1989, 111, 8551-8565.
22. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.
23. Weber, I. T.; Harrison, R. W. Molecular Mechanics Calculations on HIV-1 Protease with Peptide Substrates Correlate with Experimental Data. Protein Eng. 1996, 9, 679-690.
24. Weber, I. T.; Harrison, R. W. Molecular Mechanics Calculations on Rous sarcoma virus Protease with Peptide Substrates. Prot. Sci. 1997, 6, 2365-2374.
25. Weber, I. T.; Harrison, R. W. Molecular Mechanics Calculations on Protein-Ligand Complexes. In 3D QSAR in Drug Design. Vol. 2. Ligand-Protein Interactions and Molecular Similarity.; Kubinyi, H.; Folkers, G.; Martin, Y.; Eds.; Kluwer Academic Publishers: Dordrecht, the Netherlands, 1998; pp. 115-127.
26. Harrison, R. W.; Kurinov, I. V. Prediction of Novel Serine Protease Inhibitors. Nat. Struct. Biol. 1994, 1, 735-743.
27. Harte, W. E. J.; Beveridge, D. L. Probing structure-function relationships in humar immunodeficiency virus type 1 protesse via molecular dynamics simulation. Methods Enzymol. 1994, 241, 178-195.
28. Harrison, R. W.; Weber, I. T. Molecular dynamics simulations of HIV-1 protease with peptide substrate. Protein Eng. 1994, 7, 1353-1363.
29. Geller, M.; Miller, M.; Swanson, S. M.; Maizel, J. Analysis of the structure of HIV-1 protesse complexed with a hexapeptide inhibitor, part II: molecular dynamic studies of the active site region. Proteins 1997, 27, 195-203.
30. Liu, H.; Müller-Plathe, F.; Van Gusteren, W. F. A combined quantum/ classical molecular dynamics study of the catalytic mechanism of HIV protease. J. Mol. Biol. 1996, 261, 454-469.
31. Piana, S.; Sebastiani, D.; Carloni, P.; Parrinello, M. Ab initio molecular dynamics-based assignment of the protonation state of pepstatin A/HIV-1 protease cleavage site. J. Am. Chem. Soc. 2001, 123, 8730-8737.
32. Trylska, J.; Bala, P.; Geller, M.; Grochowski, P. Molecular dynamics simulations of the first steps of the reaction catalyzed by HIV-1 protease. Biophys. J. 2002, 83, 794-807.
33. Silva, A. M.; Cachau, R. E.; Sham, H. L.; Erickson, J. W. Inhibition and catalytic mechanism of HIV-1 aspartic protease. J. Mol. Biol. 1996, 255, 321-346.
34. Trylska, J.; Grochowski, P.; McCammon, J. A. The role of hydrogen bonding in the enzymatic reaction catalyzed by HIV-1 protease. Protein Sci. 2004, 13, 513-528.
35. Holloway, M. K.; Wai, J. M.; Halgren, T. A.; Fitzgerald, P. M.; Vacca, J. P.; Dorsey, B. D.; Levin, R. B.; Thompson, W. J.; Chen, L. J.; deSolms, S. J.; Gaffin, N.; Ghosh, A. K.; Giuliani, E. A.; Graham, S. L.; Guare, J. P.; Hungate, R. W.; Lyle, T. A.; Sanders, W. M.; Tucker, T. J.; Wiggins, M.; Wiscount, C. M.; Woltersdorf, O. W.; Young, S. D.; Darke, P. L.; Zugay, J. A. A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. J. Med. Chem. 1995, 38, 305-317.
36. Rao, B. G.; Kim, E. E.; Murcko, M. A. Calculation of solvation and binding free energy differences between VX-478 and its analogs by free energy perturbation and AMSOL methods. J. Comput. Aided Mol. Des. 1996, 10, 23-30.
37. Collins, J. R.; Burt, S. K.; Erickson, J. W. Flap opening in HIV-1 protease simulated by "activated" molecular dynamics. Nat. Struct. Biol. 1995, 2, 334-338.
38. Scott, W. R.; Schiffer, C. A. Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure 2000, 8, 1259-1265.
39. Kurt, N.; Scott, W. R.; Schiffer, C. A.; Haliloglu, T. Cooperative fluctuations of unliganded and substrate-bound HIV-1 protease: a structure-based analysis on a variety of conformations from crystallography and molecular dynamics simulations. Proteins 2003, 51, 409-422.
40. Perryman, A. L.; Lin, J. H.; McCammon, J. A. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs. Protein Sci. 2004, 13, 1108-1123.
41. Lepsik, M.; Kriz, Z.; Havlas, Z. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations. Proteins 2004, 57, 279-293.
42. Nivesanond, K.; Peeters, A.; Lamoen, D.; van Alsenoy, C. Ab Initio Calculation of the Interaction Energy in the P2 Binding Pocket of HIV-1 Protease. Int. J. Quant. Chem. 2005, 105, 292-299.
43. Hensen, C.; Hermann, J. C.; Nam, K.; Ma, S.; Gao, J.; Holtje, H. D. A combined QM/MM approach to protein-ligand interactions: polarization effects of the HIV-1 protease on selected high affinity inhibitors. J. Med. Chem. 2004, 47, 6673-6680.
44. Parish, C. A.; Yarger, M.; Sinclair, K.; Dure, M.; Goldberg, A. Comparing the conformational behavior of a series of diastereomeric cyclic urea HIV-1 inhibitors using the low mode:monte carlo conformational search method. J. Med. Chem. 2004, 47, 4838-4850.
45. Weber, I. T.; Harrison, R. W. Molecular Mechanics Analysis of Drug Resistant Mutants of HIV Protease. Protein Eng. 1999, 12, 469-474.
46. Shenderovich, M. D.; Kagan, R. M.; Heseltine, P. N.; Ramnarayan, K. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance. Protein Sci. 2003, 12, 1706-1718.
47. Rick, S. W.; Topol, I. A.; Erickson, J. W.; Burt, S. K. Molecular mechanisms of resistance: free energy calculations of mutation effects on inhibitor binding to HIV-1 protease. Protein Sci. 1998, 7, 1750-1756.
48. Chen, X.; Weber, I. T.; Harrison, R. W. Molecular Dynamics Simulations of 14 HIV Protease Mutants in Complexes with Indinavir. J. Mol. Model. 2004, 10, 373-381.
49. Piana, S.; Carloni, P.; Rothlisberger, U. Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations. Protein Sci. 2002, 11, 2393-2402.
50. Wang, W.; Kollman, P. A. Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance. Proc. Natl. Acad. Sci. USA 2001, 98, 14937-14942.
51. Schaffer, L.; Verkhivker, G. M. Predicting structural effects in HIV-1 protease mutant complexes with flexible ligand docking and protein side-chain optimization. Proteins 1998, 33, 295-310.
52. Jenwitheesuk, E.; Samudrala, R. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach. Antivir. Ther. 2005, 10, 157-166.
53. Taylor, J. S.; Burnett, R. M. DARWIN: a program for docking flexible molecules. Proteins 2000, 41, 173-191.
54. Tomioka, N.; Itai, A. GREEN: a program package for docking studies in rational drug design. J. Comput. Aided Mol. Des. 1994, 8, 347-366.
55. Makino, S.; Ewing, T. J.; Kuntz, I. D. DREAM++: flexible docking program for virtual combinatorial libraries. J. Comput. Aided Mol. Des. 1999, 13, 513-532.
56. http://www.bio.vu.nl/nvtb/Docking.html, D. P. A.
57. DesJarlais, R. L.; Seibel, G. L.; Kuntz, I. D.; Furth, P. S.; Alvarez, J. C.; Ortiz de Montellano, P. R.; DeCamp, D. L.; Babe, L. M.; Craik, C. S. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc. Natl. Acad. Sci. USA 1990, 87, 6644-6648.
58. Akaho, E.; Morris, G.; Goodsell, D.; Wong, D.; Olson, A. A Study on Docking Mode of HIV Protease and Their Inhibitors. J. Chem. Software 2001, 7, 103-114.
59. Meagher, K. L.; Carlson, H. A. Incorporating protein flexibility in structure-based drug discovery: using HIV-1 protease as a test case. J. Am. Chem. Soc. 2004, 126, 13276-13281.
60. Knegtel, R. M.; Kuntz, I. D.; Oshiro, C. M. Molecular docking to ensembles of protein structures. J. Mol. Biol. 1997, 266, 424-440.
61. Kontoyianni, M.; Sokol, G. S.; McClellan, L. M. Evaluation of library ranking efficacy in virtual screening. J. Comput. Chem. 2005, 26, 11-22.
62. Ferrara, P.; Gohlke, H.; Price, D. J.; Klebe, G.; Brooks, C. L. Assessing scoring functions for protein-ligand interactions. J. Med. Chem. 2004, 47, 3032-3047.
63. DesJarlais, R. L.; Dixon, J. S. A shape- and chemistry-based docking method and its use in the design of HIV-1 protease inhibitors. J. Comput. Aided Mol. Des. 1994, 8, 231-242.
64. Oshiro, C. M.; Kuntz, I. D.; Dixon, J. S. Flexible ligand docking using a genetic algorithm. J. Comput. Aided Mol. Des. 1995, 9, 113-130.
65. Knegtel, R. M.; Kuntz, I. D.; Oshiro, C. M. Molecular docking to ensembles of protein structures. J. Mol. Biol. 1997, 266, 424-440.
66. Joseph-McCarthy, D.; Alvarez, J. C. Automated generation of MCSS-derived pharmacophoric DOCK site points for searching multiconformation databases. Proteins 2003, 51, 189-202.
67. Clark, R. D.; Strizhev, A.; Leonard, J. M.; Blake, J. F.; Matthew, J. B. Consensus scoring for ligand/protein interactions. J. Mol. Graph Model. 2002, 20, 281-295.
68. Curioni, A.; Mordasini, T.; Andreoni, W. Enhancing the accuracy of virtual screening: molecular dynamics with quantum-refined force fields. J. Comput. Aided Mol. Des. 2004 18, 773-784.
69. Raha, K.; Merz, K. M., Jr. Large-scale validation of a quantum mechanics based scoring function: predicting the binding affinity and the binding mode of a diverse set of protein-ligand complexes. J. Med. Chem. 2005, 48, 4558-4575.
70. Huang, D.; Caflisch, A. Efficient evaluation of binding free energy using continuum electrostatics solvation. J. Med. Chem. 2004, 47, 5791-5797.
71. Radestock, S.; Bohm, M.; Gohlke, H. Improving binding mode predictions by docking into protein-specifically adapted potential fields. J. Med. Chem. 2005, 48, 5466-5479.
72. Klon, A. E.; Glick, M.; Davies, J. W. Application of machine learning to improve the results of high-throughput docking against the HIV-1 protease. J. Chem. Inf. Comput. Sci. 2004, 44, 2216-2224.
73. Sangma, C.; Chuakheaw, D.; Jongkon, N.; Saenbandit, K.; Nunrium, P.; Uthayopas, P.; Hannongbua, S. Virtual screening for anti-HIV-1 RT and anti-HIV-1 PR inhibitors from the Thai medicinal plants database: a combined docking with neural networks approach. Comb. Chem. High Throughput Screen 2005, 8, 417-429.
74. Todeschini, R.; Consonni, V. Handbook of Molecular Descriptors. In Methods and Principles in Medicinal Chemistry Series; Mannold, R.; Kubinyi, H.; Timmerman, H.; Eds.; Wiley-VCH: Weinheim and New York, 2000.
75. Xue, L.; Bajorath, J. Molecular Descriptors in Chemoinformatics, Computational Combinatorial Chemistry, and Virtual Screening. Combinatorial Chemistry & High Throughput Screening 2000, 3, 363-372.
76. Tropsha, A.; Zheng, W. Identification of the descriptor pharmacophores using variable selection QSAR: applications to database mining. Curr. Pharm. Des. 2001, 7, 599-612.
77. Adamson, G. W.; Bawden, D. A method of structure-activity correlation using Wiswesser Line Notation. J. Chem. Inf. Comput. Sci. 1975, 15, 215-220.
78. Adamson, G. W.; Bawden, D. A substructural analysis method for structure-activity correlation of heterocyclic compounds using Wiswesser line notation. J. Chem. Inf. Comput. Sci. 1977, 17, 164-171.
79. Weininger, D. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules J. Chem. Inf. Comput. Sci. 1988, 28, 31-36.
80. Weininger, D.; Weininger, A.; Weininger, J. L. SMILES. 2. Algorithm for generation of unique SMILES notation J. Chem. Inf. Comput. Sci. 1989, 29, 97-101.
81. Altschul, S. F.; Boguski, M. S.; Gish, W.; Wootton, J. C. Issues in searching molecular sequence databases. Nat. Genet. 1994, 6, 119-129.
82. Kotani, T. H.; K. Rapid Evaluation of Molecular Shape Similarity Index Using Pairwise Calculation of the Nearest Atomic Distances J. Chem. Inf. Comput. Sci. 2002, 42, 58-63.
83. Raymond, J. W.; Willett, P. Similarity Searching in Databases of Flexible 3D Structures Using Smoothed Bounded Distance Matrices. J. Chem. Inf. Comput. Sci. 2003, 43, 908-916.
84. Le, S. Y. M., J. V. Jr.; Zhang, K. In An algorithm for detecting homologues of known structured RNAs in genomes., Proc IEEE Comput Syst Bioinform Conf, 2004.
85. Park, S. H. R., K. H.; Gilbert D. Fast similarity search for protein 3D structures using topological pattern matching based on spatial relations. Int. J. Neural. Syst. 2005, 15, 287-296.
86. Xue, L.; Godden, J. W.; Bajorath, J. Mini-fingerprints for virtual screening: design principles and generation of novel prototypes based on information theory. SAR QSAR Environ. Res. 2003, 14, 27-40.
87. Mason, J. S.; Good, A. C.; Martin, E. J. 3-D pharmacophores in drug discovery. Curr. Pharm. Des. 2001, 7, 567-597.
88. Schuffenhauer, A.; Floersheim, P.; Acklin, P.; Jacoby, E. Similarity Metrics for Ligands. Reflecting the Similarity of the Target Proteins. J. Chem. Inf. Comput. Sci. 2003, 43, 391-405.
89. Fang, X. W., S. A Web-Based 3D-Database Pharmacophore Searching Tool for Drug Discovery J. Chem. Inf. Comput. Sci. 2002, 42, 192-198.
90. Volarath, P.; Wang, H.; Fu, H.; Harrison, R. W. In Knowledge-Based Algorithms for Chemical Structure and Property Analysis, International Conference of the IEEE Engineering in Medicine and Biology Society, San Francisco, CA, USA., 2004.
91. Wang, H.; Volarath, P.; Harrison, R. W. In An approach in building a chemical compound search engine in Oracle database, 27th International Conference of the IEEE Engineering in Medicine and Biology, Shanghai, China, 2005.
92. Barnard, J. M.; Downs, G. M. Clustering of chemical structures on the basis of two-dimensional similarity measures. J. Chem. Inf. Comput. Sci. 1992, 32, 644-649.
93. Fan, Y.; Shi, L. M.; Kohn, K. W.; Pommier, Y.; Weinstein, J. N. Quantitative Structure-Antitumor Activity Relationships of Camptothecin Analogues: Cluster Analysis and Genetic Algorithm-Based Studies. J. Med. Chem. 2001, 44, 3254-3263.
94. Brown, R. D.; Martin, Y. C. Use of Structure-Activity Data To Compare Structure-Based Clustering Methods and Descriptors for Use in Compound Selection. J. Chem. Inf. Comput. Sci. 1996, 36, 572-584.
95. McFarland, J. W.; Gans, D. J. Cluster significance analysis contrasted with three other quantitative structure-activity relationship methods. J. Med. Chem. 1987, 30, 46-49.
96. Draghici, S.; Potter, R. B. Predicting HIV drug resistance with neural networks. Bioinformatics 2003, 19, 98-107.
97. Patankar, S. J.; Jurs, P. C. Classification of HIV protease inhibitors on the basis of their antiviral potency using radial basis function neural networks. J. Comput. Aided Mol. Des. 2003, 17, 155-171.
98. Allen, B. C. P.; Grant G. H.; Richards, W. G. Similarity Calculations Using Two-Dimensional Molecular Representations. J. Chem. Inf. Comput. Sci. 2001, 41, 330-337.
99. Niwa, T. Prediction of biological targets using probabilistic neural networks and atom-type descriptors. J. Med. Chem. 2004, 47, 2645-2650.
100. Agrafiotis, D. K.; Lobanov, V. S.; Salemme, F. R. Combinatorial informatics in the post-genomics ERA. Nat. Rev. Drug Discov. 2002, 1, 337-346.